美泊利单抗对统一气道疾病患者SNOT-22结局的真实世界疗效评估。 - Suppr

Suppr

超能文献

Evaluation of real-world efficacy of mepolizumab on SNOT-22 outcomes in patients with unified airway disease.

作者信息

González-Pérez Ruperto, Poza-Guedes Paloma, Martín-Voso María Gabriela, Sánchez-Machín Inmaculada

机构信息

Allergy Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.

Severe Asthma Unit, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.

出版信息

Clin Transl Allergy. 2024 Nov;14(11):e70006. doi: 10.1002/clt2.70006.

DOI:10.1002/clt2.70006

PMID:39482847

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11527812/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e171/11527812/e6bf0f58d5b1/CLT2-14-e70006-g001.jpg

相似文献

Evaluation of real-world efficacy of mepolizumab on SNOT-22 outcomes in patients with unified airway disease.美泊利单抗对统一气道疾病患者SNOT-22结局的真实世界疗效评估。

Clin Transl Allergy. 2024 Nov;14(11):e70006. doi: 10.1002/clt2.70006.

Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study.美泊利珠单抗改善伴有鼻息肉的重度慢性鼻-鼻窦炎患者的健康相关生活质量和疾病症状：SYNAPSE 研究的心理测量学和疗效分析。

J Patient Rep Outcomes. 2023 Jan 20;7(1):4. doi: 10.1186/s41687-023-00543-5.

Mepolizumab Improves Outcomes of Chronic Rhinosinusitis with Nasal Polyps in Severe Asthmatic Patients: A Multicentric Real-Life Study.美泊利珠单抗改善重度哮喘患者慢性鼻-鼻窦炎伴鼻息肉的预后：一项多中心真实世界研究

J Pers Med. 2022 Aug 10;12(8):1304. doi: 10.3390/jpm12081304.

Real-world unified airway benefits of mepolizumab: Effectiveness in patients with asthma and comorbid nasal polyps.美泊利珠单抗在真实世界中的统一气道益处：对哮喘合并鼻息肉患者的有效性。

Ann Allergy Asthma Immunol. 2024 Oct;133(4):422-429.e2. doi: 10.1016/j.anai.2024.06.033. Epub 2024 Jul 6.

Sinonasal and respiratory outcomes of eosinophilic granulomatosis with polyangiitis patients receiving 100 mg mepolizumab in real-life clinical practice: 1-year follow up study.在现实临床实践中接受100毫克美泊利珠单抗治疗的嗜酸性肉芽肿性多血管炎患者的鼻窦和呼吸结局：1年随访研究

J Asthma. 2023 May;60(5):931-937. doi: 10.1080/02770903.2022.2109165. Epub 2022 Sep 14.

Comparison of the Efficacy of Omalizumab and Mepolizumab in Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease.奥马珠单抗与美泊利珠单抗治疗非甾体类抗炎药加重的呼吸道疾病的疗效比较。

Int Arch Allergy Immunol. 2024;185(10):947-952. doi: 10.1159/000539310. Epub 2024 Jun 12.

Biologics for chronic rhinosinusitis.生物制剂治疗慢性鼻-鼻窦炎。

Cochrane Database Syst Rev. 2021 Mar 12;3(3):CD013513. doi: 10.1002/14651858.CD013513.pub3.

Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study.美泊利珠单抗改善伴有鼻息肉的慢性鼻-鼻窦炎和重度嗜酸性粒细胞性哮喘患者的鼻窦-鼻部症状和哮喘控制：一项为期 12 个月的真实世界研究。

Ther Adv Respir Dis. 2021 Jan-Dec;15:17534666211009398. doi: 10.1177/17534666211009398.

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders.美泊利单抗治疗重度哮喘3年的长期疗效：与临床试验及超级应答者的比较

Biomedicines. 2023 Aug 30;11(9):2424. doi: 10.3390/biomedicines11092424.

Effectiveness and safety profile of mepolizumab in chronic rhinosinusitis with nasal polyps: Real life data in a tertiary care.美泊利珠单抗治疗慢性鼻-鼻窦炎伴鼻息肉的疗效和安全性：三级护理中的真实数据。

Am J Otolaryngol. 2024 Jul-Aug;45(4):104329. doi: 10.1016/j.amjoto.2024.104329. Epub 2024 Apr 21.

本文引用的文献

Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis.美泊利珠单抗治疗重度哮喘合并症患者：1年REALITI-A分析

J Allergy Clin Immunol Pract. 2023 Dec;11(12):3650-3661.e3. doi: 10.1016/j.jaip.2023.07.024. Epub 2023 Jul 26.

The Unified Airway Hypothesis: Evidence From Specific Intervention With Anti-IL-5 Biologic Therapy.统一气道假说：抗 IL-5 生物疗法的具体干预证据。

J Allergy Clin Immunol Pract. 2023 Sep;11(9):2630-2641. doi: 10.1016/j.jaip.2023.05.011. Epub 2023 May 18.

Mepolizumab improves quality of life and reduces activity impairments in patients with CRSwNP.美泊利珠单抗可改善伴有鼻息肉的慢性鼻窦炎患者的生活质量并减少活动损伤。

Rhinology. 2022 Dec 1;60(6):474-478. doi: 10.4193/Rhin22.053.

Type 2 inflammation in asthma and other airway diseases.哮喘及其他气道疾病中的2型炎症

ERJ Open Res. 2022 Aug 1;8(3). doi: 10.1183/23120541.00576-2021. eCollection 2022 Jul.

European Position Paper on Rhinosinusitis and Nasal Polyps 2020.欧洲鼻窦炎和鼻息肉 2020 年立场文件。

Rhinology. 2020 Feb 20;58(Suppl S29):1-464. doi: 10.4193/Rhin20.600.

The 22-Item Sinonasal Outcome Test as a Tool for the Assessment of Quality of Life and Symptom Control in Allergic Rhinitis.22项鼻鼻窦结局测试作为评估变应性鼻炎患者生活质量和症状控制情况的工具。

Am J Rhinol Allergy. 2020 Mar;34(2):209-216. doi: 10.1177/1945892419884789. Epub 2019 Nov 4.

Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence.基于推荐评估、制定与评价（GRADE）分级和真实世界证据的新一代变应性鼻炎及其对哮喘（ARIA）指南：变应性鼻炎。

J Allergy Clin Immunol. 2020 Jan;145(1):70-80.e3. doi: 10.1016/j.jaci.2019.06.049. Epub 2019 Oct 15.

Minimal clinically important difference for the 22-item Sinonasal Outcome Test in medically managed patients with chronic rhinosinusitis.慢性鼻-鼻窦炎患者经药物治疗后 22 项鼻鼻窦结局测试的最小临床重要差异。

Clin Otolaryngol. 2018 Oct;43(5):1328-1334. doi: 10.1111/coa.13177. Epub 2018 Jul 26.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验